-
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Monday, August 12, 2024 - 11:50am | 412Read More...Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC). Under the terms of the agreement, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66...
-
FDA Expands Allergan's BOTOX Label To Include Eight New Muscles In Patients With Upper Limb Spasticity
Thursday, July 29, 2021 - 10:44am | 165Read More...The FDA has approved a label expansion of Allergan's, an AbbVie Inc (NYSE: ABBV) company, BOTOX (onabotulinumtoxinA) to include eight new muscles to treat upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and...
-
Allergan's BOTOX Wins FDA Nod For Neurologic Condition-Associated Pediatric Detrusor Overactivity
Wednesday, February 10, 2021 - 12:05pm | 177Read More...The FDA has approved Allergan and AbbVie Inc's (NYSE: ABBV) BOTOX (onabotulinumtoxinA). It is used to treat detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response...
-
Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved
Monday, January 29, 2018 - 11:39am | 392Read More...Allergan plc Ordinary Shares (NYSE: AGN) is down 26 percent over the last six months, but one analyst said there's only upside to its sickly state. The biotech’s trajectory inspired an upgrade from a three-year Hold. The Rating Barclays analyst Douglas Tsao upgraded Allergan to a Buy...
-
Botox Competition Spurs Argus To Downgrade Allergan
Thursday, December 7, 2017 - 1:18pm | 446Read More...Shares of Allergan plc Ordinary Shares (NYSE: AGN) continue trading near their multi year low of $160.07, with many investors concerned with a competitive environment that will intensify in the coming years. The Analyst Argus' David Toung downgraded Allergan's stock rating from Buy to...
-
Analyst Says Negative Allergan Headlines Are Priced In, Upgrades Stock
Wednesday, November 29, 2017 - 9:48am | 463Read More...Allergan plc Ordinary Shares (NYSE: AGN) have seen heavy selling pressure throughout parts of 2017, but some analysts are encouraging investors to take advantage of the weakness. The Analyst Morgan Stanley's David Risinger upgraded Allergan's stock rating from Equal-weight to Overweight...
-
Apple, JPMorgan Among Top Picks On New List From UBS
Thursday, September 14, 2017 - 3:28pm | 812Read More...Analysts at UBS published a list of their highest conviction calls among all of the firm's analysts across North America. Here is a sample of some of the names that are ranked as the firm's "highest conviction Buy-rated investment ideas in North America today." Allergan Allergan plc Ordinary Shares...
-
Credit Suisse Presents Bull And Bear Cases For Allergan
Tuesday, August 16, 2016 - 10:01am | 444Read More...Analysts at Credit Suisse presented the bull and bear cases for Allergan plc Ordinary Shares (NYSE: AGN) in a research note on Monday. The analysts see the stock trading at $329 as a "base case" scenario, $391 under a "bull case" scenario and $200 under a "bear case" scenario. The Bull Case Under...
-
JPMorgan On Allergan: Solid Core Product Performance
Wednesday, May 11, 2016 - 9:14am | 297Read More...JPMorgan has maintained its Overweight rating on Allergan plc Ordinary Shares (NYSE: AGN), saying that the double-digit growth in the company's brands business is expected to continue throughout the year. Allergan's first quarter adjusted earnings of $3.04 a share topped the Street's estimate of $3...
-
Citi Maintains Its Constructive Stance On Allergan
Wednesday, May 11, 2016 - 9:01am | 299Read More...Citi has maintained its Buy rating on Allergan plc Ordinary Shares (NYSE: AGN), saying the performance of the core brands "should not be overlooked." Allergan's first-quarter adjusted earnings of $3.04 per share topped the Street's estimate of $3.01. The company's adjusted top line grew 48.1...
-
Citigroup Says Actavis Is Now Worth $360 Per Share (And It's A Buy)
Wednesday, March 11, 2015 - 9:10am | 227Read More...In a report published Tuesday, Citigroup analyst Liav Abraham commented on a recent meeting with Actavis plc's (NYSE: ACT) senior management team in London that increased his confidence in a "swift and successful" integration of Allergan, Inc. Abraham noted that key growth...
-
Apple And 4 Other Environmentally Responsible Companies
Friday, July 11, 2014 - 8:22am | 926Read More...Environmental responsibility is more than a buzzword for many of the world’s largest corporations. In addition to the notion of protecting the environment, companies have found that ‘going green’ can have a positive impact on the bottom line. Here are five companies that take...
-
Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)
Tuesday, April 22, 2014 - 1:24pm | 589Read More...Over the past couple of days there has been news of several multi-billion dollar deals in the pharmaceutical sector. The big news came on Monday night when it began to leak that Valeant Pharmaceuticals (NYSE: VRX) was going to make a bid for Allergan (NYSE: AGN), the maker of Botox. The deal...
-
MAP Skyrockets Off the Map on Allergan Acquisition
Wednesday, January 23, 2013 - 1:23pm | 389Read More...MAP Pharmaceuticals (NASDAQ: MAPP) is blasting into orbit today on word the company will be acquired by Irvine, California drug manufacturer Allergan (NYSE: AGN). On Tuesday, MAP announced Allergan will purchase 100 percent of its shares at $25 each. Overall, the value of the purchase is an...
